ASCEND BY NTHRYS
Research Abroad Products

Genomics Project Topics

Browse all focused areas across all project categories under this field.

Showing 2089–2100 of 2250 project topics
Synthetic Lethal Interaction Screening in Disease Models
A specialized genomics screening platform that identifies synthetic lethal gene pairs and drug combinations using CRISPR libraries applied to disease-relevant cellular and animal models. This generates revenue through screening contracts with pharmaceutical and biotech companies seeking novel drug targets and combination therapy opportunities.
Functional Genomics in Disease Models Click to view more details →
Disease Model Epigenetic Landscape Mapping and Profiling
A comprehensive epigenomics service platform offering ChIP-seq, ATAC-seq, and methylation analysis of disease models to uncover regulatory mechanisms and non-genetic drivers of disease phenotypes. Revenue is driven through tiered service packages, data licensing, and integration partnerships with drug discovery and development teams.
Functional Genomics in Disease Models Click to view more details →
Clear Cell RCC VHL and Chromatin Modifier Genomics
Characterizing VHL, PBRM1, SETD2, and BAP1 inactivation patterns in ccRCC by WGS for molecular subtype and prognosis classification.
Genomics of Renal Cell Carcinoma Click to view more details →
Non-Clear Cell RCC Genomic Classification
Applying WGS and RNA-seq for characterizing papillary, chromophobe, and translocation RCC for molecular diagnosis and treatment guidance.
Genomics of Renal Cell Carcinoma Click to view more details →
RCC mTOR Pathway Genomic Analysis
Profiling mTOR pathway gene mutations for guiding everolimus and temsirolimus treatment selection in metastatic RCC.
Genomics of Renal Cell Carcinoma Click to view more details →
Immunotherapy Response Genomics in RCC
Identifying genomic predictors of anti-PD-1 response in RCC using WGS-derived TMB, HLA type, and tumor microenvironment analysis.
Genomics of Renal Cell Carcinoma Click to view more details →
RCC Tumor Mutational Burden Quantification SaaS Platform
A cloud-based diagnostic platform that analyzes whole genome sequencing data to calculate precise TMB scores and predict immunotherapy response in RCC patients. This enables oncology clinics and pharmaceutical companies to stratify patients for checkpoint inhibitor trials and personalized treatment protocols, generating recurring revenue through per-sample processing fees.
Genomics of Renal Cell Carcinoma Click to view more details →
Metastatic RCC Genomic Driver Mutation Detection Tool
A targeted sequencing analysis tool that identifies actionable driver mutations in metastatic RCC including BAP1, PBRM1, and KDM5C alterations using optimized bioinformatics pipelines. Hospitals and cancer centers monetize this through licensed software agreements and integration with their laboratory information systems for precision oncology programs.
Genomics of Renal Cell Carcinoma Click to view more details →
RCC Angiogenesis Pathway Gene Expression Profiling Service
A commercial genomics service that measures expression levels of VEGF signaling genes and hypoxia-response pathways to predict anti-angiogenic therapy efficacy in RCC patients. Pharmaceutical companies and clinical laboratories utilize this biomarker service to support drug development, patient stratification, and companion diagnostic commercialization.
Genomics of Renal Cell Carcinoma Click to view more details →
RCC Chromosomal Instability Index Prediction Analytics Engine
An AI-powered analytics platform that quantifies chromosomal instability patterns and copy number variations to predict RCC prognosis and treatment resistance mechanisms. This tool generates value through licensing agreements with cancer centers, enabling risk stratification services and integration into clinical decision support systems for premium margins.
Genomics of Renal Cell Carcinoma Click to view more details →
Hereditary RCC Syndrome Genomic Screening Commercial Kit
A targeted sequencing panel detecting germline mutations in hereditary RCC genes including VHL, FLCN, SDH, and FH for family screening and early intervention programs. Diagnostic laboratories and genetic testing companies commercialize this as a high-margin clinical test with accompanying interpretation software and genetic counseling support services.
Genomics of Renal Cell Carcinoma Click to view more details →
RCC Epigenetic Biomarker Database Platform Enterprise License
An enterprise genomics database and analytics platform housing methylation patterns, histone modification data, and regulatory variant information curated specifically for RCC patient stratification. Pharmaceutical companies, CROs, and academic centers license this platform to accelerate drug discovery, biomarker validation, and personalized medicine research generating annual subscription revenue.
Genomics of Renal Cell Carcinoma Click to view more details →